uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

uniQure N.V.NASDAQ: QURE

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash grows, but more slowly than its trailing trend

Q1 FY2026 net change in cash of $59.74M rose 2.4% year over year, behind the +180.0% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -37.9% a year.

Context

  • Net change in cash amounted to 488.8% of revenue in FY2025, up 178.3 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +2.4% toward the trailing-twelve-month pace of +180.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$59.74M+111.6% QoQ
Last fiscal yearDec 2025
-$78.69M-6.6% YoY
LTMMar 2026
-$77.19M+180.0% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.4%——
1 year-6.6%——
3-year CAGR-37.9%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(78.69M) USD
Year-over-year change
+6.6%

Net Change in Cash vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 net change in cash of $77.19M is the 2nd largest of the 8 companies compared; the peer median is $221K.
  • Its year-over-year change of +180.0% is the highest of 8, against a peer median of -49.8%.
  • Net change in cash amounts to 426.6% of revenue for QURE, versus a peer median of 77.6%.
QURE Competitors Peer median
Net Change in Cash for QURE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$114.88M -770.6%-54.7%130.8%
QUREuniQure N.V.LTM Mar 2026$77.19M +180.0%-37.9%426.6%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$68.48M -51.8%-4.0%77.6%
NGNENeurogene Inc.LTM Mar 2026$53.39M +167.3%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$46.18M +174.8%—6.9%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$34.32M -49.8%-30.5%94.0%
MGTXMeiraGTx Holdings plcLTM Mar 2026$5.19M +110.1%+19.1%6.5%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$221K -101.5%-2.2%—
Peer median (excluding QURE) $221K-49.8%-4.0%77.6%

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
Deferred Income Tax3.21M(1.47M)1.92M2.43M1.59M
Stock-Based Compensation25.64M34.2M35.09M22.26M17.68M
Change in Working Capital(50.48M)(43.38M)81.12M(3.94M)(6.79M)
Accounts Receivables(58.96M)(49.08M)(1.32M)(2.24M)(8.6M)
Inventory0(6.92M)(6.74M)2.42M0
Accounts Payables(727K)9.24M(4.17M)1.52M(2.67M)
Other Working Capital9.2M3.39M93.36M(5.64M)4.47M
Other Non-Cash Items(27.29M)(16.16M)32.51M23.44M(6.23M)
Operating Cash Flow287.96M(145.06M)(145.93M)(182.73M)(177.96M)
Capital Expenditures(17.44M)(17.69M)(7.15M)(3.37M)(439K)
Acquisitions (Net)(49.95M)(1.9M)000
Purchases of Investments0(163.15M)(366.44M)(359.84M)(658.37M)
Sales of Investments00167.91M534.5M337.2M
Other Investing Activities00000
Investing Cash Flow(67.39M)(182.73M)(205.69M)162.97M(321.62M)
Debt Repayment62.5M0370.06M(53.05M)0
Common Stock Issued33.7M1.45M308K2.12M391.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.33M)0(7.65M)(8.56M)23.5M
Financing Cash Flow94.86M1.45M362.72M(59.49M)415.4M
Effect of Forex Changes(3.76M)(1.83M)2.27M(4.97M)5.49M
Net Change in Cash311.67M(328.18M)13.37M(84.22M)(78.69M)
Free Cash Flow270.52M(162.75M)(153.08M)(186.1M)(177.96M)

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.